

11-28-00

A/Re

Please type a plus sign (+) inside this box → ☐

PTO/SB/50 (08-00)

Approved for use through 12/30/2000 OMB 0651-0033

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## REISSUE PATENT APPLICATION TRANSMITTAL

JC406 U.S. PTO  
09/24/378  
11/27/00

Address to:

Assistant Commissioner for Patents  
Box Reissue  
Washington, DC 20231

Attorney Docket No

183-114

First Named Inventor

S. Margolin

Original Patent Number

6,114,353

Original Patent Issue Date  
(Month/Day/Year)

Sept. 5, 2000

Express Mail Label No

EL424883788

## APPLICATION FOR REISSUE OF:

(Check applicable box)



Utility Patent



Design Patent



Plant Patent

## APPLICATION ELEMENTS (37 CFR 1.173)



Fee Transmittal Form (PTO/SB/56)

(Submit an original, and a duplicate for fee processing)



Applicant claims small entity status. See 37 CFR 1.27.

Specification and Claims in double column copy of patent  
format (amended, if appropriate)

Drawing(s) (proposed amendments, if appropriate)

Reissue Oath/Declaration (original or copy)  
(37 C.F.R. § 1.175) (PTO/SB/51 or 52)

Original U.S. Patent currently assigned?



Yes



No

(If Yes, check applicable box(es))



Written Consent of all Assignees (PTO/SB/53)

37 C.F.R. § 3.73(b) Statement  
(PTO/SB/96)Power of  
Attorney

## ACCOMPANYING APPLICATION PARTS

7

Statement of status/support for all changes to  
the claims. See 37 CFR 1.173 (c).

8



Original U.S. Patent for surrender



Ribboned Original Patent Grant



Statement of Loss (PTO/SB/55)

9.

Foreign Priority Claim (35 U.S.C. 119)  
(if applicable)

10

Information Disclosure  
Statement (IDS)/PTO-1449Copies of IDS  
Citations

11.

English Translation of Reissue Oath/Declaration  
(if applicable)

12



Preliminary Amendment

13

Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)

14

Other

## 15. CORRESPONDENCE ADDRESS



Customer Number or Bar Code Label

21091

or

☐ Correspondence address below

(Insert Customer No. or Attach bar code label here)

Name

Address

City

State

Zip Code

Country

Telephone

Fax

NAME

(Print/Type)

John H. Crozier

Registration No. (Attorney/Agent)

30,371


Signature

Date

Nov. 27, 2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Reissue, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number

REISSUE APPLICATION FEE TRANSMITTAL FORM						Docket Number (Optional) 183-114		
Claims as Filed - Part 1								
Claims in Patent		Number Filed in Reissue Application	(3) Number Extra	Small Entity		Other than a Small Entity		
				Rate	Fee	Rate	Fee	
(A)	Total Claims (37 CFR 1.16(j))	(B)	**** =	x \$ _____ =		or	x \$ _____ =	
(C)	Independent claims (37 CFR 1.16(j))	(D)	* =	x \$ _____ =			x \$ _____ =	
Basic Fee (37 CFR 1.16(h))					\$ 355			\$ _____
Total Filing Fee					\$ 355		OR \$ _____	
Claims as Amended - Part 2								
	(1) Claims Remaining After Amendment		(2) Highest Number Previously Paid For	(3) Extra Claims Present	Small Entity		Other than a Small Entity	
					Rate	Fee	Rate	Fee
Total Claims (37 CFR 1.16(j))	***	MINUS	**	=	x \$ _____ =		x \$ _____ =	
Independent Claims (37 CFR 1.16(j))	***	MINUS	*****	=	x \$ _____ =		x \$ _____ =	
Total Additional Fee					\$		OR \$	
<p>If the entry in (D) is less than the entry in (C), Write "0" in column 3</p> <p>*** If the "Highest Number of Total Claims Previously Paid For" is less than 20, Write "20" in this space.</p> <p>*** After any cancellation of claims.</p> <p>*** If "A" is greater than 20, use (B - A), if "A" is 20 or less, use (B - 20)</p> <p>***** "Highest Number of Independent Claims Previously Paid For" or Number of Independent Claims in Patent (C).</p> <p><input checked="" type="checkbox"/> Applicant claims small entity status See 37 CFR 1.27</p> <p><input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ A duplicate copy of this sheet is enclosed.</p> <p><input type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees under 37 CFR 1.16 or 1.17 which may be required, or credit any overpayment to Deposit Account No. _____ A duplicate copy of this sheet is enclosed.</p> <p><input type="checkbox"/> A check in the amount of \$ _____ to cover the filing / additional fee is enclosed.</p> <p><input checked="" type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.</p> <p><b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b></p>								
Nov. 27, 2000				 Signature of Applicant, Attorney or Agent of Record <u>John H. Crozier</u> Typed or printed name				
Date								

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REISSUE APPLICATION BY THE INVENTOR,  
OFFER TO SURRENDER PATENT**

Docket Number (Optional)

183-114

This is part of the application for a reissue patent based on the original patent identified below.

Name of Patentee(s)

Solomon B. Margolin

Patent Number

6,114,353

Date Patent Issued

Title of Invention

COMPOSITIONS AND METHOD FOR TREATMENT OF LYMPHOMAS, LEUKEMIAS, AND LEIOMYOMAS

I am the inventor of the original patent.

I offer to surrender the original patent.

1. ☐ Filed herein is a certificate under 37 CFR 3.73(b).
2. ☒ Ownership of the patent is in the inventor(s), and no assignment of the patent has been made.

One of boxes 1 or 2 above must be checked.

The written consent of all assignees owning an undivided interest in the original patent is included in this application for reissue.

Signature

Solomon B. Margolin

Date

Oct 28, 2000

Typed or printed name

Solomon B. Margolin

The assignee owning an undivided interest in said original patent is \_\_\_\_\_,  
and the assignee consents to the accompanying application for reissue.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application, any patent issued thereon, or any patent to which this declaration is directed.

Name of assignee

Signature of person signing for assignee

Date

Typed or printed name and title of person signing for assignee

PATENT  
183-114

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re US Patent Application of )  
Solomon B. Margolin )  
Reissue of US Patent No. 6,114,353 )  
Filed: Simultaneously herewith. )  
Title: COMPOSITIONS AND METHOD FOR )  
TREATMENT OF LYMPHOMAS, )  
LEUKEMIAS, AND LEIOMYOMAS ) Date: November 27, 2000

Assistant Commissioner for Patents  
Washington DC 20231


"EXPRESS MAIL" MAILING LABEL NO. EL424883788  
DATE OF DEPOSIT: NOVEMBER 27, 2000

Dear Sir:

I hereby certify that the above-identified reissue application is being deposited by me, postage prepaid, with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date set forth above, addressed to BOX REISSUE, Assistant Commissioner for Patents, Washington DC 20231.

Date: November 27, 2000.

Respectfully submitted,

  
John H. Crozier  
Reg. No. 30,371  
1934 Huntington Turnpike  
Trumbull CT 06611-5116  
Tel: (203) 375-9118  
Fax: (203) 378-8108

PATENT  
183-114

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re US Patent Application of )  
Solomon B. Margolin )  
Reissue of US Patent No. 6,114,353 )  
Filed: Simultaneously herewith. )  
Title: COMPOSITIONS AND METHOD FOR )  
TREATMENT OF LYMPHOMAS, )  
LEUKEMIAS, AND LEIOMYOMAS ) Date: November 27, 2000

Assistant Commissioner for Patents  
Washington DC 20231

PRELIMINARY AMENDMENT

Dear Sir:

Please amend US Patent No. 6,114,353 as follows:

IN THE TITLE:

Please change the title to ---METHODS FOR TREATMENT OF  
BENIGN AND MALIGNANT TUMORS, INCLUDING LYMPHOMAS, LEUKEMIAS,  
AND LEIOMYOMAS---.

IN THE ABSTRACT:

Please cancel the last two lines thereof and insert  
therefor ---as agent(s) for treating benign and malignant  
tumors, including lymphomas, leukemias, and leiomyomas---.

IN THE SPECIFICATION:

At column 1, line 53, following "In", please insert  
---benign and malignant tumors including---.

At column 6, line 10, following "in", please insert  
---benign and malignant tumors including---.

At column 8, line 34, please cancel "of" and insert  
therefor ---on---.

At column 8, line 35, please cancel "indicate" and  
insert therefor ---indicates---.

At column 9, lines 2 and 3, please cancel "neoplasia"  
and insert therefor ---neoplastic---.

At column 9, line 9, please cancel "anti-neoplasia"  
and insert therefor ---anti-neoplastic---.

At column 9, line 20, following "effective" please  
insert ---human---.

At column 9, line 23, please cancel "250 to about 750" and insert therefor ---25 to about 50---.

At column 9, line 24, please cancel "which dosage may be taken in the diet" and insert therefor ---taken with meals and a beverage---.

IN THE CLAIMS:

Please amend the following claims as follows:

1. (amended) A method of treating benign or malignant tumors including lymphomas,...

4. (amended) A method of treating benign or malignant tumors including lymphomas,...

REMARKS

Entry of the above amendment is respectfully requested.

In the above-referenced patent, Applicant claimed less than he had a right to claim by reason of the disclosure.

It is believed that the amendment to Claims 1 and 4 is fully supported by the disclosure as filed. See, for example, column 5, lines 65-67, to column 6, lines 1-6. Claims 1 and 4 have been amended to more particularly point out and distinctly claim that the method is applicable to the treatment of benign tumors. Claims 2 and 3 are unchanged. No claims have been amended.

Other sections have been amended to reinforce this or the clarify the language thereof. Support for the amendments to column 9, lines 20 and 23, may be found, for example, in Claim 3 of the patent.

In view of the above amendments and remarks, it is respectfully submitted that the claims in the application, Claims 1-4, as amended, are allowable and early action in that regard is respectfully requested.



PRELIMINARY AMENDMENT  
REISSUE OF P/N 6,114,353

PATENT  
183-114

Should any questions remain as to the allowability of the claims or should the Examiner have any suggestions with respect thereto, the undersigned would be grateful for the privilege of a telephone conference with the Examiner.


Date: November 27, 2000.

Respectfully submitted,



John H. Crozier  
Reg. No. 30,371  
1934 Huntington Turnpike  
Trumbull CT 06611-5116  
Tel: (203) 375-9118  
Fax: (203) 378-8108

I hereby certify that this correspondence is being deposited today with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

  
\_\_\_\_\_  
John H. Crozier  
Date 11/27/00 Regis. No. 30,371



Urb 114353A

## United States Patent [19]

**[11] Patent Number: 6,114,353**

**Margolin**

[45] **Date of Patent:** Sep. 5, 2000

[54] COMPOSITIONS AND METHOD FOR TREATMENT OF LYMPHOMAS, LEUKEMIAS, AND LEIOMYOMAS

[76] Inventor: **Solomon B. Margolin**, 6723 Desco Dr.,  
Dallas, Tex. 75225

[21] Appl. No.: 09/239,211

[22] Filed: Jan. 28, 1999

### Related U.S. Application Data

[63] Continuation-in-part of application No. 09/162,011, Sep. 28, 1998, which is a continuation-in-part of application No. 08/913,202, Sep. 3, 1997, abandoned, which is a continuation-in-part of application No. PCT/US96/02737, Mar. 4, 1996, which is a continuation-in-part of application No. 08/397,962, Mar. 3, 1995, abandoned.

[51] **Int. Cl.<sup>7</sup>** ..... **A61K 31/44; A61K 31/47**

[52] U.S. Cl. .... 514/313; 514/334; 514/336;  
514/341; 514/342; 514/345

[58] **Field of Search** ..... 514/345, 342,  
514/341, 336, 313, 334

## [56] References Cited

## U.S. PATENT DOCUMENTS

4,042,699 8/1977 Gadekar ..... 514/345

4,052,509	10/1977	Gadekar	514/345
-----------	---------	---------	---------

*Primary Examiner*—Jerome D. Goldberg  
*Attorney, Agent, or Firm*—John H. Crozier

[57] **ABSTRACT**

In a preferred embodiment, drugs having chemotherapeutic properties which are useful against certain neoplastic disorders with wide safety margins as evidenced by their low toxicity, and molecular actions. Such drugs include as active ingredient(s) one or more N-substituted 2-(1H) pyridone(s) and/or N-substituted 3-(1H) pyridone(s). The compositions of this invention are novel as anti-neoplastic drugs, namely as an agent for treating leukemias, lymphomas, and leiomyomas.

**4 Claims, 4 Drawing Sheets**